Could This Be the Next Blockbuster Indication for Eli Lilly?

Submitted by admin on October 21, 2021 - 10:37am

Source:

Motley Fool

News Tags:

Headline:

snippet:

Alopecia areata patients receiving Olumiant were much more likely to experience significant scalp hair regrowth than those who took a placebo.
Olumiant probably won't quite be a blockbuster for Eli Lilly, but it will be a meaningful growth driver for the stock regardless.
Eli Lilly is a dividend growth stock that investors should consider.

Search form